A enhances AI-powered lab software, automation and digital workflows to support drug discovery, biopharma research and long-term growth.
Agilent (A) reported earnings 30 days ago. What's next for the stock?
Canadian Apartment Properties REIT trades at 15x AFFO and nearly 40% below NAV, offering compelling value. Q1 AFFO per share declined just 1.5% to C$0.513, with a strong 70% payout ratio and robust distribution coverage. Active buybacks and retained AFFO (~C$100 million/year) support growth initiatives and the development pipeline.
| Professional Services Industry | Industrials Sector | Padraig McDonnell CEO | XMIL Exchange | US00846U1016 ISIN |
| US Country | 17,900 Employees | 30 Jun 2026 Last Dividend | 3 Nov 2014 Last Split | - IPO Date |
Agilent Technologies, Inc. stands as a global provider offering application-focused solutions primarily to the life sciences, diagnostics, and applied chemical sectors. The company propagates its mission across three distinct segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab, ensuring a broad spectrum of scientific research, diagnostic, and analytical needs are met worldwide. Since its establishment in 1999, Agilent has cemented its headquarters in Santa Clara, California, from where it orchestrates its global operations, offering an expansive portfolio through direct sales, distributors, resellers, and electronic commerce frameworks.